SLC12A4

Across TCGA pan-cancer cohorts, SLC12A4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC12A4 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC12A4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC12A4 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where SLC12A4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.336	0.707	<.001	44	view →
LSCC	OS	Tertile	II,III,IV	0.545	0.911	.003	44	view →
LUAD	DFS	Median	II,III,IV	0.688	0.968	.004	30	view →
CCRCC	OS	Median	IV	0.451	1.000	.016	25	view →
HNSC	OS	Tertile	All	0.911	0.776	.016	11	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC12A4–PDAC (DFS)

Open the PDAC breakdown →